This study is not the major mover. It’s the Illucix for prostate cancer that is more important. 24/9 is when we will hear if US FDA approves its use. Then UK/Europe, Canada and Australia come next.
Ann: Telix Supporting Amgen PSMA-Targeting Therapy Trial, page-8
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.13 |
Change
-0.340(1.75%) |
Mkt cap ! $6.401B | |||
| Open | High | Low | Value | Volume |
| $19.41 | $19.46 | $18.81 | $121.0M | 6.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7316 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.13 | 6814 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |